Mirum Pharma (MIRM) Earnings Call Transcript

Mirum reported Q3 net product revenue of $133M, up 47% YoY, and delivered GAAP net income of ~$3M with cash, cash equivalents and investments of $378M (up $85M YTD). Management updated 2025 revenue guidance to $500–$510M and highlighted LIVMARLI net sales of $92M ($64M U.S., $28M international) plus $41M from bile acid medicines; $5M of Takeda-related Japan sales were recognized in the quarter with no expected Takeda sales in Q4. Clinical progress includes completed enrollment in the Phase IIb VISTAS study (volixibat/PSC) with top-line data expected in Q2 2026, ongoing VANTAGE and EXPAND enrollment, and initiation of a Phase II MRM-3379 study; management projects peak sales >$1B for several assets. Overall, the beat, profitability milestone, stronger cash position and upward guidance are materially positive and likely supportive for the stock near term.

Analysis

Mirum’s trajectory is best read through optionality rather than levelized earnings: three clinical programs create multiple binary value inflection points and, separately, a commercial base that can be lumpy because of distributor/order timing and partner inventory dynamics. The lumpy international channel creates seasonal or quarter-level noise that can both magnify upside on good readouts and accelerate downside if partner ordering pauses; that pattern is a predictable source of volatility that savvy traders can exploit around catalysts.

The company’s move to a solid-tablet formulation and ongoing label-expansion studies are subtle but high-leverage commercial levers — improving adherence in older patients increases estimated patient lifetime revenue and lowers churn, which matter more than headline launch dollars for valuation multiples in rare-disease franchises. Simultaneously, the firm’s posture on IP and selective BD reduces dilution risk and positions it as an acquirer-of-last-resort—likely to buy de-risked, near-term assets rather than early-stage bets, which compresses execution risk but keeps upside concentrated in its own pipeline readouts.

Primary risks that can reverse the current sentiment are clinical/regulatory setbacks on the pruritus-driven approval path, near-term safety signals in sicker, comorbid populations that alter label or usage, and competitive launches that reframe pricing benchmarks for bile-acid/IBAT markets. Payer pushback or conservative uptake in adult hepatology (where genetic testing is still patchy) are multi-quarter drags; conversely, a clean positive readout would likely re-rate the equity sharply given limited near-term dilution and a clear commercialization playbook.

Key Decisions for Investors

• Long MIRM equity (ticker: MIRM) size 1–2% NAV ahead of the next PSC/pruritus readout window; hedge tail risk with a modest out-of-the-money put (10–15% notional) expiring ~12 months. R/R: asymmetric — limited carry cost, binary upside from clean readout versus controlled downside from hedge.
• Call-spread structure to express binary clinical upside: buy MIRM 9–12 month call spread (buy near-the-money, sell 1.5–2x strike) to cap cost while retaining >3x potential return if clinical readouts surprise positively. Timeframe: monitor implied vols and initiate 2–8 weeks before expected topline to avoid the steepest IV ramp.
• If risk-averse, trade the lumpy international cycle: buy on pronounced sequential weakness driven by distributor pause and sell into recovery; use options to size exposure. Mechanism: take small long-equity or long-call position after partner inventory comments, and trim on confirmation of reorder cadence — typical holding period 1–3 months.
• Avoid broad short of large-cap competitor GSK on IBAT/linerixibat chatter; instead, use a limited pair: long MIRM / short a small portion of established PBC/PPAR commercialization names to hedge class-price compression risk. Timeframe: 6–18 months, reassess post-readouts and any competitive approvals.